Anti-Soluble RANK Antibody - BSA and Azide free (A283739)

Anti-Soluble RANK Antibody - BSA and Azide free

Rabbit polyclonal antibody to Soluble RANK.

This antibody recognises CD265 also known as RANK, TNFRSFIIA, osteoclast differentiation factor receptor and receptor activator of NF-?B. This antibody recognises the soluble TNFR homologous cysteine rich portion of the extracellular domain of the CD265 receptor. CD265 has major functions in bone remodeling, signaling to regulate osteoclast formation, activation and survival in normal bone modeling and remodeling in an array of pathological conditions characterized by upregulated bone turnover. CD265 signaling is induced upon binding of its ligand RANKL which results in the recruitment of one of several adapter proteins including TRAF6. This can result in the activation of the NF-?B, MAPK or c-Src signaling pathways. Beyond its crucial function in osteoclastogenesis, CD265 has also been implicated in other physiological processes including immunotolerance, organogenesis of the immune system and osteoimmunology.

WB, ELISA

ELISA: 0.5 µg/ml - 2.0 µg/ml, WB: 0.1 µg/ml - 0.2 µg/ml

Human

E. coli derived recombinant human soluble CD265containing the TNFR-homologous, cysteine-rich portion of the extracellular domain of RANK receptor.

Rabbit

Polyclonal

IgG

Lyophilized

Reconstitute with 0.1 ml Phosphate Buffered Saline and 0.1% Bovine Serum Albumin.

Supplied in Phosphate Buffered Saline.

Lyophilized: Store at -20°C. Reconstituted: Store undiluted at -20°C, avoid freeze / thaw cycles. Storage in frost free freezers is not recommended. Should this product contain a precipitate we recommend microcentrifugation before use.

Rabbit anti Human CD265 (soluble) antibody, recognizes CD265 also known as RANK, TNFRSFIIA, osteoclast differentiation factor receptor and receptor activator of NF-?B. This antibody recognizes the soluble TNFR homologous cysteine rich portion of the extracellular domain of the CD265 receptor. CD265 has major functions in bone remodeling, signaling to regulate osteoclast formation, activation and survival in normal bone modeling and remodeling in an array of pathological conditions characterized by upregulated bone turnover (Boyce & Xing 2008). CD265 signaling is induced upon binding of its ligand RANKL which results in the recruitment of one of several adapter proteins including TRAF6. This can result in the activation of the NF-?B, MAPK or c-Src signaling pathways (Nagy & Penninger 2015). Beyond its crucial function in osteoclastogenesis, CD265 has also been implicated in other physiological processes including immunotolerance, organogenesis of the immune system and osteoimmunology (Sigl et al. 2016).